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ischemic or bleeding events or 1-year cardiovascular events in a large population of
patients undergoing PCI.
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Background: In patients with ST-segment elevation myocardial infarction (STEMI)
undergoing primary percutaneous coronary intervention (PCI), unfractionated heparin
(UFH), low molecular weight heparin (LMWH), fondaparinux, or bivalirudin are
treatment options. The relative beneﬁts of each of these regimen merits more sys-
tematic investigation.
Methods: We conducted a Medline/EMBASE/CENTRAL search for randomized
trials (RCT) comparing parenteral antithrombotic therapies for patients undergoing
primary PCI. Five treatment groups were identiﬁed: UFH+Glycoprotein IIbIIIa
inhibitor (GPI), UFH, bivalirudin, fondaparinux or LMWH+GPI. The primary
ischemic outcome was short-term (in-hospital/30-days) major adverse cardiovas-
cular event (MACCE); the primary bleeding outcome was short-term major
bleeding.
Results: We identiﬁed 23 RCTs that enrolled 22899 patients. In the MTC models,
when compared with UFH+GPI, UFH (OR¼1.48; 95% CI 1.18-1.86), bivalirudin
or fondaparinux (numerically higher) were associated with higher MACCE.
Similarly, when compared with LMWH+GPI, UFH (OR¼2.63; 95% CI 1.28-5.26),
bivalirudin (OR¼2.27; 95% CI 1.09-4.76) and fondaparinux (OR¼3.12; 95% CI
1.27-7.69) were associated with a higher MACCE. LMWH+GPI, followed by
UFH+GPI, bivalirudin, UFH and fondaparinux were the hierarchy for treatment
efﬁcacy for MACCE (highest to lowest rank). For bleeding, when compared with
UFH+GPI, both UFH (OR¼0.70; 95% CI 0.55-0.89) and bivalirudin (OR¼0.61;
95% CI 0.47-0.79) were associated with lower major bleeding. Bivalirudin, fol-
lowed by UFH, LMWH+GPI, UFH+GPI and fondaparinux were the hierarchy for
treatment safety (highest to lowest rank). Results were similar in direct comparison
meta-analyses: bivalirudin was associated with a 37% increase in MI, 44% increase
in urgent revascularization, and an 81% increase in stent thrombosis when
compared with UFH or UFH+GPI but with a 43% decrease in major bleeding
when compared with UFH+GPI with no difference when compared with UFH
alone.
Conclusions: In patients undergoing primary PCI, UFH+GPI and LMWH+GPI were
most efﬁcacious with the lowest MACCE rate, whereas bivalirudin was safest with the
lowest bleeding.
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Background: The use of anticoagulants in the setting of acute myocardial infarction
can lead to improvement of short-term survival by costing the increase of bleeding
risk. We performed a meta-analysis of all randomized data that has evaluated the
clinical outcomes among those patients admitted for acute STEMI and that received
either heparin or bivalirudin.
Methods: Pub Med, Chocrane and Scopus were systematically searched up to May
2014. Subjects of analysis were 30 days mortality, AMI, Target Lesion Revascular-
ization, major revascularization, and in-stent thrombosis. We used Fixed or Random
Effect analysis using the Cochrane Handbook of Systematic Reviews.
Results: A total of 3 studies provided a total of 7629 patients, being 3804 in the
bivalirudin group and 3825 patients in the heparin group. There was a strong trend
(p¼0.11) towards decreased AMI in the heparin group, with associated signiﬁcant
decrease of TLR and in-stent thrombosis (p< 0.05). Major bleeding trended towards
the heparin group (Figure 1).
Conclusions: Our analysis suggests that heparin might be associated with better
outcomes at post STEMI event, although there was no mortality beneﬁt. Some of
those beneﬁts might be due to decreased in stent thrombosis. Therefore large ran-
domized studies are warranted.B138 JACC Vol 64/11/Suppl B j SeptemberPharmacotherapy - GPIIb/IIIa inhibitors
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Background: Excess dosing of antithrombotic agents has been associated with
adverse outcomes. To date, dosing errors have not been studied in pts speciﬁcally
undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes
(ACS).
Methods: Analysis was performed in pts who received recommended (labeled
dosing) vs. excess eptiﬁbatide bolus or infusion doses during PCI in the HORI-
ZONS-AMI and ACUITY trials. Adverse outcome rates were assessed. Multivar-
iable analysis was performed to determine predictors of excess dosing and adverse
events.
Results: Of 5,287 pts (840 STEMI, 4,447 NSTEACS) treated with eptiﬁbatide, 543
(10.3%) were administered doses outside the recommended range (including in 319
of 574 pts (56%) with renal dysfunction [creatinine clearance < 50 mL/min].
Predictors of excess dosing included STEMI presentation, baseline creatinine
clearance, baseline hematocrit, and hypertension. Pts who received excess dosing
experienced higher rates of adverse outcomes (Table). By multivariable analysis,
excess dosing was independently associated with 30-day non-CABG major bleeding
(HR [95%CI] ¼ 1.38 [1.05, 1.82], p¼0.02) but not 30-day or 1-year all-cause
mortality (HR [95%CI] ¼ 1.47 [0.79, 2.74], p¼0.22, and 1.26 [0.84, 1.88], p¼0.27,
respectively].
Conclusions: In this large-scale study, excess dosing of eptiﬁbatide during PCI
for ACS was common (even in the clinical trial setting), and was an inde-
pendent predictor of major bleeding but not early or late mortality. Quality
control efforts to ensure proper dosing may improve outcomes in high-risk
ACS pts.13–17, 2014 j TCT Abstracts/Pharmacotherapy - GPIIb/IIIa inhibitors
Table. Thirty-Day and One-Year Outcomes
Thirty-Day
Outcomes
Excess Dose
(N¼543)
Recommended
Dose (N¼4,744) HR [95%CI] p-Value
All-cause death 17 (3.1) 56 (1.2) 2.70
[1.59, 4.76]
0.0002
Reinfarction 39 (7.3) 301 (6.4) 1.15
[0.83, 1.61]
0.41
Stent thrombosis
(def/prob)
16 (3.0) 79 (1.7) 1.82
[1.06, 3.13]
0.03
Non-CABG major
bleeding
69 (12.8) 329 (7.0) 1.89
[1.47, 2.44]
<0.0001
MACE 57 (10.5) 399 (8.5) 1.27
[0.96, 1.69]
0.09
NACE 106 (19.6) 650 (13.8) 1.49
[1.20, 1.82]
<0.0001
One-Year Outcomes
All-cause death 40 (7.5) 148 (3.7) 2.44
[1.72, 3.45]
<0.0001
Reinfarction 62 (11.8) 415 (9.1) 1.33
[1.03, 1.75]
0.03
Stent thrombosis
(def/prob)
18 (3.4) 113 (2.6) 1.45
[0.88, 2.38]
0.15
MACE 114 (21.3) 772 (17.3) 1.33
[1.10, 1.61]
0.004
Values presented as n (%). MACE¼Major Adverse Cardiovascular Events (death, myocardial
infarction unplanned revascularization for ischemia, stroke); NACE¼Net Adverse Clinical
Events (MACE or major bleeding).
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMTCT-473
Efﬁcacy and safety of abciximab administration in contemporary primary
percutaneous coronary intervention
Julio García-Tejada1, Jurado-Roman Alfonso1, Carolina Granda1,
Agustin Albarran1, Felipe Henandez1, M. Teresa Velazquez1,
Roberto Martin-Asenjo1, Belen Rubio1, Sandra Mayordomo1, Juan C. Tascon1
1University Hospital 12 de Octubre, Madrid, Spain
Background: With the widespread use of high loading dose of clopidogrel or new
P2Y12 receptor inhibitors, limited data are available regarding the efﬁcacy and safety
of the administration of a glycoprotein IIb/IIIa inhibitor to patients with ST-segment
elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary
intervention (PPCI). Thus, we analyzed the short-term results of abciximab admin-
istration to a contemporary cohort of STEMI patients undergoing PPCI.
Methods: Between July-2012 and April-2014, 482 STEMI patients underwent PPCI
in a tertiary care hospital. All patients were preloaded with aspirin and a thienopir-
idine. 94% of the patients were treated with unfractioned heparin and 6% with
bivalirudin. PPCI was performed via transradial approach in 84% of cases. We
compared the clinical characteristics and the 30-day outcome between 2 groups of
patients: those treated with abciximab (group A, n¼287) and those treated without
(group B, n¼195).
Results: Patients in group A were younger, more frequently men, had more body
weight, hypertension, multivessel disease and thrombus burden than patients in group
B. Preloading with clopidogrel (group A: 78% vs group B: 73%, p¼0.2) and/or with a
new P2Y12 receptor inhibitor (group A: 30% vs. group B: 38%, p¼0.1) was similar in
both groups. At 30 days, the efﬁcacy endpoint (composite of death, reinfarction, new
target-vessel revascularization or ischemic stroke) was observed less frequently in
group A than in group B (5.5% vs. 11.7%, respectively, p¼0.02), while the safety
endpoint (BARC type 3 bleeding) occurred similarly in both groups of patients
(group A: 4.1% vs. group B: 3.5%, p¼0.7). The net adverse clinical event rate
(combination of the efﬁcacy and safety endpoints) was also similar in both groups of
patients (group A: 9.7%vs. group B: 15.3%, p¼0.06).
Conclusions: In contemporary PPCI, administration of abciximab to selected patients
appears safe and effective, and is potentially associated with a reduction in adverse
ischemic event rate, without an increase in major bleeding risk.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/PhaPharmacotherapy - Chronic anticoagulants
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Background: Current guidelines recommend dual antiplatelet therapy (DAPT) in
patients with acute coronary syndrome (ACS) treated with percutaneous coronary
intervention (PCI) and anticoagulation for stroke protection in patients with atrial
ﬁbrillation (AF) and CHADS2 scores 2, but optimum antithrombotic therapy in
patients with AF undergoing PCI for ACS remains controversial.
Methods: Among 859 consecutive patients with AF treated with PCI in the AVIA-
TOR (Antithrombotic strategy Variability InATrial ﬁbrillation and Obstructive coro-
nary disease Revascularized with PCI) registry, 425 presented with ACS. Patients
were stratiﬁed according to medications at discharge: triple therapy (TT; warfarin +
DAPT) or DAPT (aspirin + clopidogrel). Major adverse cardiovascular events
(MACE; death, myocardial infarction, stroke) and clinically relevant bleeding (BARC
2) were compared between groups over 1 year.
Results: Mean age was similar in the 2 groups (74  9 years). Patients receiving TT
(n¼185, 43.5%) were more often male with higher ejection fraction and more likely to
receive bare metal stents than patients discharged on DAPT (n¼240, 56.5%). The
1-year incidence of MACE was similar in the TT vs. DAPT groups (14 vs. 16%,
adjusted HR 0.9; p¼0.78) but patients on TT more often developed bleeding (13 vs.
6%, adjusted HR 2.05 p¼0.03; Figure).
Conclusions: DAPT was more often prescribed in these patients with AF and
CHADS2 scores 2 undergoing PCI for ACS. Compared to patients on DAPT, those
given TT had similar 1-year rates of MACE but more bleeding.TCT-475
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Background: Optimal antithrombotic regimen for patients with atrial ﬁbrillation (AF) un-
dergoing drug-eluting stent (DES) implantation for complex coronary artery disease is un-
certain.Theaimof study is to compare thenet clinical outcomesbetween triple antithrombotic
therapy group (TAT; aspirin, thienopyridine and warfarin) and dual antiplatelet therapy
group (DAPT; aspirin and thienopyridine) in AF patients undergoing DES implantation.
Methods: Among a total of 367 AF patients undergoing DES implantation, 154 pa-
tients (42.0%) received TAT and 213 patients (58.0%) received DAPT. The prescribedrmacotherapy - Chronic anticoagulants (warfarin and newer agents) B139
